Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial
| Autor: | Kenneth W. Mahaffey, Jagadish Gogate, Matthew R. Weir, C.V. Damaraju, Ricardo Correa-Rotter |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Population Type 2 diabetes Endocrinology Internal medicine Post-hoc analysis Internal Medicine Medicine Humans cardiovascular diseases Canagliflozin education Sodium-Glucose Transporter 2 Inhibitors education.field_of_study Clinical Trials as Topic business.industry Proportional hazards model Hazard ratio Hispanic or Latino medicine.disease Stroke Diabetes Mellitus Type 2 Cardiovascular Diseases Cohort business Mace medicine.drug Glomerular Filtration Rate |
| Zdroj: | Diabetes, obesitymetabolismREFERENCES. 24(1) |
| ISSN: | 1463-1326 |
| Popis: | Aims People with type 2 diabetes mellitus (T2DM) have a greater risk of cardiovascular disease and major adverse cardiovascular events (MACE), which become more common as kidney function declines. Canagliflozin reduced the risk of MACE (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) in patients with T2DM and high cardiovascular risk or nephropathy in the CANVAS Program and CREDENCE trial. Risk of MACE by kidney status had not been examined in Hispanic participants. Materials and methods This post hoc analysis included integrated, pooled data from the CANVAS Program and CREDENCE. The effects of canagliflozin versus placebo on MACE were assessed in subgroups by baseline eGFR ( 60mL/min/1.73 m2 ) overall and in the Hispanic cohort. Hazard ratios (HRs) and 95% CIs were estimated using Cox regression models, with subgroup by treatment interaction terms added to test for heterogeneity. Results A total of 14,543 participants were included; 3029 (20.8%) self-identified as Hispanic. In the overall population, canagliflozin reduced the risk of MACE compared with placebo (HR, 0.83; 95%CI, 0.75, 0.92), with no heterogeneity observed across eGFR subgroups (interaction P=0.22). In the Hispanic cohort, canagliflozin also reduced the risk of MACE (HR, 0.71; 95%CI, 0.55, 0.92) with no heterogeneity by baseline eGFR (interaction P=0.25), including among the highest-risk Hispanic participants with baseline eGFR Conclusion Canagliflozin reduced the risk of MACE overall and among Hispanic participants with T2DM and high cardiovascular risk or nephropathy in the CANVAS Program and CREDENCE, without heterogeneity by baseline eGFR. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text